Sometimes regulators change their minds, and when they do, biotech companies pay the price. Atara Biotherapeutics (ATRA) learned this lesson the hard way on Monday when shares tanked more than 50% after the Food and Drug Administration rejected its cell therapy application for the second time, but with a completely different rationale.

The FDA issued a Complete Response Letter rejecting EBVALLO (tabelecleucel) for treating Epstein-Barr virus-positive post-transplant lymphoproliferative disease in adults and children aged two and older who have received at least one prior therapy. This is a serious and life-threatening complication that can occur after organ or stem cell transplants, where immunosuppression allows EBV to drive uncontrolled B-cell growth.

Trading volume exploded to 2.75 million shares compared to the typical daily average of just 92,283, reflecting the severity of the setback for the struggling biotech.

The FDA's About-Face

Here's where things get frustrating for Atara and its partner. The company had resubmitted its Biologics License Application in 2025 after reaching what it believed was clear alignment with the FDA on how to address the issues raised in the first Complete Response Letter from January 2025.

That first rejection was straightforward: the FDA cited a single deficiency regarding Good Manufacturing Practice compliance. Notably, the agency raised no concerns about safety, efficacy, or trial design at that time.

In Monday's rejection letter, the FDA confirmed that Atara had satisfactorily resolved the GMP compliance issues and again raised no safety concerns. So far, so good.

But then came the curveball. The FDA now claims that the single-arm ALLELE trial, which it had previously confirmed as adequate to support the application, is no longer considered sufficient to provide evidence of effectiveness for accelerated approval. The agency stated that the trial's interpretability is compromised due to issues with study design, conduct, and analysis.

This represents a complete reversal from the FDA's prior guidance to Atara. The agency had previously aligned with the company on the clinical trial dataset and accepted the single-arm study design as appropriate for this patient population when the BLA was originally submitted.

A New Player Steps In

Adding another layer to this story, Atara transferred the BLA to Pierre Fabre Pharmaceuticals Inc., the U.S. subsidiary of Pierre Fabre Laboratories, back in November 2025. So Pierre Fabre is now dealing with this regulatory whiplash.

Pierre Fabre has already announced its intention to request a Type A meeting with the FDA, which should be granted within 45 days. Both Pierre Fabre and Atara plan to engage urgently with the agency to identify a path forward for timely accelerated approval of EBVALLO.

Financial Strain Mounting

The timing couldn't be worse for Atara. The company ended 2025 with just $8.5 million in cash, cash equivalents, and short-term investments. That's a razor-thin cushion for a biotech company navigating regulatory obstacles.

To preserve capital, Atara implemented a brutal 90% workforce reduction in 2025 and transferred all tabelecleucel activities and associated costs to Pierre Fabre Laboratories. In December, the companies amended their commercialization agreement to mitigate the financial impact of rebuilding commercial inventory in the United States.

Under the revised terms, Atara agreed to reduce the milestone payment due upon BLA approval from an undisclosed amount to $31 million in exchange for the right to receive an additional $15 million in potential milestone payments down the line.

Atara Biotherapeutics shares closed down 52.74% at $6.46 on Monday, marking a devastating day for investors who had hoped the regulatory path would be clearer after addressing the manufacturing concerns.